Prospective interventional clinical study to evaluate the efficacy and safety of atezolizumab plus bevacizumab in combination with carbon ion radiotherapy for unresectable hepatocellular carcinoma
Not Applicable
Recruiting
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000051549
- Lead Sponsor
- Yamagata University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with untreated or poorly treated esophageal aneurysms and/or gastric varices with or judged to be at high risk for bleeding. Patients who have undergone esophagogastroduodenoscopy (EGD) prior to enrollment, have been examined and treated for varices, and have been determined to be at low risk for bleeding will be eligible for enrollment. (EGD will not be required if performed within 6 months prior to starting atezolizumab/bevacizumab combination therapy.) Patients who are deemed inappropriate by the principal investigator or study investigators to participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Over survival+Progression-free survival for carbon ion radioherapy and Atezolizumab/Bevacizumab Combination Therapy
- Secondary Outcome Measures
Name Time Method Objective response rate and Incidence of side effects